Find all the latest information in acute myeloid leukemia, arranged by types, translocations, and mutations. Listed below are recently updated categories.
TP53 mutations in the determination of azacitidine response for older patients with AML
Optimal treatment strategies for older patients with acute myeloid leukemia (AML) are elusive and the overall...
Eprenetapopt receives FDA Fast Track designation for the treatment of AML
On November 30, 2020, it was announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to...
Positive topline results from a phase II trial of antroquinonol for patients with AML
On November 26, 2020, a press release on topline results from a phase II trial (NCT03823352) of antroquinonol in...
Molecular mechanisms associated with leukemic transformation of PV and ET
Leukemic transformation in patients with polycythemia vera (PV) and essential thrombocythemia (ET) is considered a leading...
The history and evolution of the role of venetoclax in the treatment of AML
Despite only being approved in the last few years, venetoclax has already become a standard of care for treating patients...
Beat AML Master trial: can we use precision medicine to treat older patients with AML?
The Beat AML Master trial is an umbrella study which contains 11 sub-studies covering the most prominent subtypes...
Addition of nucleoside analogues to 7+3: A case report of high-risk AML
During the 2nd How to Diagnose and Treat Acute Leukaemia conference of the European School of Haematology (ESH), Nigel Russell...
Venetoclax plus 10-day decitabine in chemotherapy-ineligible patients with newly diagnosed or R/R AML
The prognosis of acute myeloid leukemia (AML) in older patients is usually poor, due to the...
Core binding factor
Epigenetic modifier mutations
Signaling pathway mutations
Transcription factor mutations
Tumor suppressor mutations